mrc

Antibody humanization is a rapid and reliable developmental process which offers:

• Short clinical developmental times
• High regulatory approval rates
• Better management of risk

Our Biotherapeutics group (part of MRCTs Centre for Therapeutics Discovery) has substantial antibody engineering know-how. To take advantage of our expertise please contact Dr John Kelly or complete this form.

Humanized antibodies to novel targets

We have been humanizing antibodies for the better part of quarter of a century and our expertise has been used by the world’s leading pharmaceutical and biotech companies.

The technique we use (CDR grafting) was developed at the MRC giving our scientists unrivalled knowledge about this specialised discipline. We also offer other engineering services such as affinity maturation and biophysical characterisation.

Our experts have humanized more than 50 antibodies, which include two marketed products: Tysabri and Actemra. A further six are in clinical trials (including Vedolizumab), with two more in preclinical studies.

No upfront fees

We do not charge an upfront fee to companies for our humanization service, with our return coming from success milestone payments and a small product royalty.

Universities and charities

We offer a shared-risk collaboratation model to institutions wishing to humanize their antibody portfolio.